Published in J Infect Dis on May 15, 2008
B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 2.50
Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children. Eur J Pediatr (2012) 1.49
Vaccination against hepatitis b virus: are Italian medical students sufficiently protected after the public vaccination programme? J Occup Med Toxicol (2015) 1.44
Hepatitis B immunization strategies: timing is everything. CMAJ (2009) 1.18
Hepatitis B virus: where do we stand and what is the next step for eradication? World J Gastroenterol (2014) 1.03
Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen. J Clin Immunol (2010) 0.96
Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother (2012) 0.89
Gender difference of alanine aminotransferase elevation may be associated with higher hemoglobin levels among male adolescents. PLoS One (2010) 0.89
Comparison of long-term immunogenicity (23 years) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children. Hum Vaccin Immunother (2012) 0.87
Immune persistence after hepatitis B vaccination in infancy - Fact or fancy? Hum Vaccin Immunother (2016) 0.86
Long-term T-cell-mediated immunologic memory to hepatitis B vaccine in young adults following neonatal vaccination. Hepat Mon (2014) 0.86
The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology (2013) 0.85
Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine. Hum Vaccin Immunother (2013) 0.85
Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. PLoS One (2011) 0.84
Unsolved problems and future perspectives of hepatitis B virus vaccination. World J Gastroenterol (2015) 0.84
Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization. Hum Vaccin Immunother (2013) 0.82
Impact of universal vaccination against hepatitis B: the italian model. Hepat Mon (2012) 0.81
A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen. J Infect Dis (2016) 0.77
The one year effects of three doses of hepatitis B vaccine as a booster in anti-HBs-negative children 11-15 years after primary immunization; China, 2009-2011. Hum Vaccin Immunother (2015) 0.77
Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites. Med Microbiol Immunol (2016) 0.77
Evaluation of hepatitis B surface antibody and specific gamma interferon response in health care workers after vaccination. Jundishapur J Microbiol (2014) 0.76
Seroconversion of Hepatitis B Vaccine in Young Children in the Kassena Nankana District of Ghana: A Cross-Sectional Study. PLoS One (2015) 0.75
The effects of booster vaccination on hepatitis B vaccine in anti-HBs negative infants of HBsAg-positive mothers after primary vaccination. Hum Vaccin Immunother (2013) 0.75
Twenty years of universal vaccination against hepatitis B in Italy: achievements and challenges. J Public Health Res (2012) 0.75
Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China. Hum Vaccin Immunother (2016) 0.75
The effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children 5-15 y after primary immunization; China, 2009-2010. Hum Vaccin Immunother (2013) 0.75
Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study. BMC Public Health (2014) 0.75
Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine. Medicine (Baltimore) (2016) 0.75
Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate. Open Access Maced J Med Sci (2016) 0.75
Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon. World J Hepatol (2016) 0.75
Lessons learnt over two decades of vaccination against hepatitis B in Italy. J Prev Med Hyg (2015) 0.75
The effects of booster vaccination on combined hepatitis A and hepatitis B vaccine in both anti-HBs and anti-HAV negative children 5-15 years after hepatitis B vaccine primary immunization. Hum Vaccin Immunother (2013) 0.75
Hepatitis B virus surface antigen and antibody markers in children at a major paediatric hospital after the pentavalent DTP-HBV-Hib vaccination. Ghana Med J (2017) 0.75
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Global control of hepatitis B virus infection. Lancet Infect Dis (2002) 3.74
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis (2008) 3.01
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial. Crit Care Med (2013) 2.88
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology (2004) 2.74
Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis (2008) 2.70
Genome sequencing and comparative analysis of Klebsiella pneumoniae NTUH-K2044, a strain causing liver abscess and meningitis. J Bacteriol (2009) 2.64
Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. J Clin Microbiol (2002) 2.64
Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol (2005) 2.58
Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol (2013) 2.58
Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med (2007) 2.56
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol (2007) 2.48
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol (2009) 2.40
Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis (2003) 2.36
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Universal screening for biliary atresia using an infant stool color card in Taiwan. Hepatology (2008) 2.32
Novel swine-origin influenza virus A (H1N1): the first pandemic of the 21st century. J Formos Med Assoc (2009) 2.28
Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis (2003) 2.26
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis (2012) 2.17
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol (2004) 2.10
Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology (2010) 2.10
Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology (2011) 2.07
Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis (2003) 2.00
Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther (2014) 1.99
An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2006) 1.99
Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol (2012) 1.98
An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis (2011) 1.96
SARS in healthcare facilities, Toronto and Taiwan. Emerg Infect Dis (2004) 1.95
The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis (2002) 1.90
High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology (2006) 1.87
Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem (2004) 1.86
Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics (2009) 1.85
RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology (2005) 1.85
Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis (2006) 1.84
An interferon-gamma-related cytokine storm in SARS patients. J Med Virol (2005) 1.83
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol (2009) 1.82
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Establishing a nationwide emergency department-based syndromic surveillance system for better public health responses in Taiwan. BMC Public Health (2008) 1.81
Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol (2002) 1.80
Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology (2010) 1.78
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2011) 1.77
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol (2002) 1.76
Complete nucleotide sequence of pK245, a 98-kilobase plasmid conferring quinolone resistance and extended-spectrum-beta-lactamase activity in a clinical Klebsiella pneumoniae isolate. Antimicrob Agents Chemother (2006) 1.76
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology (2007) 1.75